VIVANZA BIOSCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.55 INR | -1.50% |
|
-14.38% | -39.18% |
| 04-30 | Vivanza Biosciences Limited Announces Directors Resignation | CI |
| 04-30 | Vivanza Biosciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 280 | 79.8 | 52.4 | 522.4 | 754.6 | 752 |
| Enterprise Value (EV) 1 | 322.9 | 124.6 | 84.05 | 556.9 | 809.1 | 830.3 |
| P/E ratio | 137 x | -18.1 x | -25.5 x | 693 x | 227 x | 126 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 4.35 x | 3 x | 0.54 x | 5.28 x | 6.74 x | 4.14 x |
| EV / Revenue | 5.01 x | 4.69 x | 0.87 x | 5.63 x | 7.22 x | 4.57 x |
| EV / EBITDA | - | - | - | 440,901,331 x | 108,398,951 x | 71,359,605 x |
| EV / FCF | -29.2 x | 34.9 x | 7.25 x | -148 x | - | -30.8 x |
| FCF Yield | -3.43% | 2.86% | 13.8% | -0.68% | - | -3.25% |
| Price to Book | 7.51 x | 2.43 x | 1.7 x | 16.5 x | 21.6 x | 18.4 x |
| Nbr of stocks (in thousands) | 40,000 | 40,000 | 40,000 | 40,000 | 40,000 | 40,000 |
| Reference price 2 | 7.000 | 1.995 | 1.310 | 13.06 | 18.86 | 18.80 |
| Announcement Date | 14/08/18 | 07/09/19 | 16/09/20 | 16/09/21 | 29/06/22 | 01/07/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 64.41 | 26.59 | 96.21 | 98.88 | 112 | 181.5 |
| EBITDA | - | - | - | 1.263 | 7.464 | 11.64 |
| EBIT 1 | 6.034 | -0.2243 | 2.294 | 1.165 | 7.39 | 11.61 |
| Operating Margin | 9.37% | -0.84% | 2.38% | 1.18% | 6.6% | 6.39% |
| Earnings before Tax (EBT) 1 | 2.335 | -4.409 | -2.057 | 1.235 | 3.334 | 7.164 |
| Net income 1 | 2.054 | -4.409 | -2.057 | 0.7534 | 3.33 | 5.983 |
| Net margin | 3.19% | -16.58% | -2.14% | 0.76% | 2.97% | 3.3% |
| EPS 2 | 0.0510 | -0.1102 | -0.0514 | 0.0188 | 0.0830 | 0.1496 |
| Free Cash Flow 1 | -11.06 | 3.567 | 11.59 | -3.774 | - | -26.95 |
| FCF margin | -17.17% | 13.41% | 12.05% | -3.82% | - | -14.84% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 14/08/18 | 07/09/19 | 16/09/20 | 16/09/21 | 29/06/22 | 01/07/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 42.9 | 44.8 | 31.6 | 34.5 | 54.5 | 78.3 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | 27.32 x | 7.304 x | 6.727 x |
| Free Cash Flow 1 | -11.1 | 3.57 | 11.6 | -3.77 | - | -26.9 |
| ROE (net income / shareholders' equity) | 5.66% | -12.6% | -6.46% | 2.41% | 10% | 15.8% |
| ROA (Net income/ Total Assets) | 4.36% | -0.13% | 1.22% | 0.7% | 4.34% | 3.81% |
| Assets 1 | 47.15 | 3,345 | -168.4 | 107.7 | 76.69 | 156.8 |
| Book Value Per Share 2 | 0.9300 | 0.8200 | 0.7700 | 0.7900 | 0.8700 | 1.020 |
| Cash Flow per Share 2 | -0.7400 | -0.7500 | -0.6900 | -0.7700 | -0.6700 | 0.0400 |
| Capex | - | - | - | 0.21 | - | - |
| Capex / Sales | - | - | - | 0.21% | - | - |
| Announcement Date | 14/08/18 | 07/09/19 | 16/09/20 | 16/09/21 | 29/06/22 | 01/07/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -39.18% | 3.14M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- VIVANZA6 Stock
- Financials Vivanza Biosciences Limited
